3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
6
Sarcoma
3
Pancreatic Neoplasms
2
Nasopharyngeal Carcinoma
2
Colorectal Neoplasms
2
Whole-Brain Radiotherapy
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Recurrence
1
Pancreatic Adenocarcinoma Metastatic
1
Ovarian Cancer Recurrent
1
Neoplasm Metastasis
1
Locally Advanced Thyroid Gland Carcinoma
1
Leiomyosarcoma
1
Kidney Neoplasms
1
Hyperthermia
1
HER2-Negative Breast Cancer
1
Gallbladder Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Craniopharyngioma
1
Cholangiocarcinoma
1
Interventions
Specimen Handling
4
Gemcitabine
3
Doxorubicin
3
liposomal doxorubicin
2
Trabectedin
2
Magnetic Resonance Spectroscopy
2
Dacarbazine
2
Biopsy
2
toripalimab
1
regorafenib
1
peposertib
1
cemiplimab
1
anlotinib
1
abemaciclib
1
X-Rays
1
Tretinoin
1
Tissue Banks
1
Tablets
1
Surgical Procedures, Operative
1
Standard of Care
1
Rosuvastatin Calcium
1
Radiotherapy
1
Quality of Life
1
Nivolumab
1
Neoadjuvant Therapy
1
Midazolam
1
Injections
1
Immunoglobulin G
1
Ifosfamide
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leiomyosarcoma
×
anlotinib
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled